$GOVXW News

Last published 1y ago

1y agoGOVX GOVXWGeoVax Receives Notice of Allowance For Cancer Vaccine PatentGlobeNewswireAdds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against
1y agoGOVX GOVXWGeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceGlobeNewswireATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO,
1y agoGOVX GOVXWGeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGlobeNewswireGEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and
1y agoGOVX GOVXWGeoVax Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireProgress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2
2y agoGOVX GOVXWGeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and
2y agoGOVX GOVXWGeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman &
2y agoGOVX GOVXWGeoVax to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its
2y agoGOVX GOVXWGeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-MarketGlobeNewswireATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced
2y agoGOVX GOVXWRegistration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEOGlobeNewswireCompany to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc.
2y agoGOVX GOVXWGeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketGlobeNewswireATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced
2y agoGOVX GOVXWGeoVax to Present at the Emerging Growth Conference on August 21, 2024GlobeNewswireCompany to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc.
2y agoGOVX GOVXWGeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory BoardGlobeNewswireStrategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
2y agoGOVX GOVXWGeoVax Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireAwarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents
2y agoGOVX GOVXWUpdate: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee ReviewGlobeNewswireCompany plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a
2y agoGOVX GOVXWGeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee ReviewGlobeNewswireCompany plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a
2y agoGOVX GOVXWGeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against
2y agoGOVX GOVXWGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineGlobeNewswirePresentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies
2y agoGOVX GOVXWGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressGlobeNewswireATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
2y agoGOVX GOVXWGeoVax to Present at the 36th Annual Roth ConferenceGlobeNewswireATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced
2y agoGOVX GOVXWGeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemGlobeNewswireManufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a
2y agoGOVX GOVXWGeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateGlobeNewswireProgress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck
2y agoGOVX GOVXWGeoVax to Present at the 2024 BIO CEO & Investor ConferenceGlobeNewswireATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced
2y agoGOVX GOVXWGeoVax Announces Multiple Patent Issuances and AllowancesGlobeNewswireIntellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a
2y agoGOVX GOVXWGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterGlobeNewswireResults Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company
2y agoGOVX GOVXWGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementGlobeNewswireATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious
2y agoGOVX GOVXWGeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyGlobeNewswireStrengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
2y agoGOVX GOVXWGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsGlobeNewswireTherapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax
2y agoGOVX GOVXWGeoVax Announces Issuance of Malaria Vaccine PatentGlobeNewswirePatent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
2y agoGOVX GOVXWGeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024GlobeNewswireATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
2y agoGOVX GOVXWGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxGlobeNewswireATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
2y agoGOVX GOVXWGeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine CongressGlobeNewswire80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
2y agoGOVX GOVXWGeoVax to Participate in Upcoming December Investor EventsGlobeNewswireATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
2y agoGOVX GOVXWGeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressGlobeNewswirePresentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28, 2023
2y agoGOVX GOVXWProgress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023GlobeNewswireSingle-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
3y agoGOVX GOVXWGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireSignificant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference
3y agoGOVX GOVXWGeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023GlobeNewswireGeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and
3y agoGOVX GOVXWGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineGlobeNewswireDesigned to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
3y agoGOVX GOVXWGeoVax to Participate in Upcoming November Investor and Industry EventsGlobeNewswireATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
3y agoGOVX GOVXWGeoVax Update: Clinical and Operational Progress Toward Transformative OpportunitiesGlobeNewswireATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
3y agoGOVX GOVXWGeoVax Receives Notice of Allowance for Marburg Vaccine PatentGlobeNewswireATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
3y agoGOVX GOVXWGeoVax Receives Notice of Allowance for HIV Vaccine PatentGlobeNewswireATLANTA, GA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
3y agoGOVX GOVXWGeoVax to Participate in Upcoming October Investor and Industry EventsGlobeNewswireCompany to Provide Updates on Phase 2 Clinical Trialsfor Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax
3y agoGOVX GOVXWGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentGlobeNewswireATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and
3y agoGOVX GOVXWGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceGlobeNewswirePreclinical Data for GEO-CM02 Demonstrates Single-Dose ProtectionAgainst Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a
3y agoGOVX GOVXWGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised PatientsGlobeNewswireData Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing human vaccines and
3y agoGOVX GOVXWGeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireUpdates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company
3y agoGOVX GOVXWGeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine BoosterGlobeNewswireMulti-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing
3y agoGOVX GOVXWGeoVax to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireCompany to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX),
3y agoGOVX GOVXWGeoVax to Present at the Emerging Growth Conference on September 6, 2023GlobeNewswireCompany to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire
3y agoGOVX GOVXWGeoVax Receives Notice of Allowance for Malaria Vaccine PatentGlobeNewswirePatent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing